08:57 AM EST, 01/12/2026 (MT Newswires) -- ADMA Biologics ( ADMA ) said Monday it now estimates its 2025 revenue at between $510 million and $511 million, compared with at least $510 million previously.

Two analysts polled by FactSet expect $510.9 million.

The company said it continues to expect 2025 adjusted net income of $158 million and adjusted earnings before interest, taxes, depreciation and amortization of $235 million.

For 2026, the company updated its revenue projection to about $635 million, compared with at least $630 million previously. Two analysts polled by FactSet expect $631.9 million.

The company reaffirmed its 2026 adjusted net income of about $255 million and raised its adjusted EBITDA guidance to about $360 million from $355 million previously.

For 2027, total revenue is expected to be about $775 million. Two analysts surveyed by FactSet expect $771 million.

Adjusted EBITDA and adjusted net income are projected at about $455 million and about $315 million, respectively.

Shares of the company were up over 1% in recent Monday premarket activity.